{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:34:13Z","timestamp":1787592853915,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100020549","name":"Centre Leon Berard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijgc.2025.101669","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:41:05Z","timestamp":1738168865000},"page":"101669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Controversies in the organization and structure of management for rare tumors"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ijgc.2025.101669_bib1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101669_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.canep.2013.08.001","article-title":"Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project","volume":"37","author":"Mallone","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101669_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ijgc.2025.101669_bib4","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/1078-0432.CCR-22-1206","article-title":"Gene-expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes","volume":"28","author":"Meagher","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101669_bib5","first-page":"487","article-title":"Ovarian cancer epidemiology in the era of collaborative team science","volume":"28","author":"Cannioto","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101669_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/GCO.0000000000000508","article-title":"Molecular characterization of endometrial cancer and therapeutic implications","volume":"31","author":"Chang","year":"2019","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101669_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2010.05.023","article-title":"Management of rare ovarian cancers: the experience of the French website \u201cObservatory for rare malignant tumours of the ovaries\u201c by the GINECO group: interim analysis of the first 100 patients","volume":"119","author":"Ray-Coquard","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101669_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ijgc-2023-004599","article-title":"European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors","volume":"33","author":"Joneborg","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101669_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2020.02.012","article-title":"The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study","volume":"157","author":"Lenck","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101669_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijgc.2025.101669_bib11","unstructured":"Small Cell Ovarian Cancer Foundation. https:\/\/smallcellovarian.org\/."},{"issue":"12","key":"10.1016\/j.ijgc.2025.101669_bib12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdq257","article-title":"Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience","volume":"21","author":"Alexandre","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101669_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101669_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ygyno.2022.03.019","article-title":"Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)","volume":"165","author":"Henno","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101669_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101669_bib16","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1634\/theoncologist.2018-0121","article-title":"Relevance of reference centers in sarcoma care and quality item evaluation: results from the prospective registry of the Spanish group for research in sarcoma (GEIS)","volume":"24","author":"Martin-Broto","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101669_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158406","article-title":"Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)","volume":"12","author":"Derbel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijgc.2025.101669_bib18","article-title":"Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ijgc.2025.101669_bib19","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.14694\/EdBook_AM.2014.34.e282","article-title":"Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges","author":"Ledermann","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101669_bib20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/annonc\/mdx099","article-title":"Networking for ovarian rare tumors: a significant breakthrough improving disease management","volume":"28","author":"Chiannilkulchai","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101669_bib21","article-title":"International Journal of Gynecological Cancer. Editorial","volume":"24","author":"Ray-Coquard","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101669_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101669_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101669_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101669_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101669_bib26","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10324","key":"10.1016\/j.ijgc.2025.101669_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.101669_bib28","series-title":"Trametinib in Recurrent or Progressive Low Grade Serous Ovarian Cancer (Adults)","year":"2023"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101669_bib29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.5849","article-title":"Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas","volume":"256","author":"Heinze","year":"2022","journal-title":"J Pathol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2500194X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2500194X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:40:24Z","timestamp":1772329224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2500194X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1048891X2500194X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101669","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the organization and structure of management for rare tumors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101669"}}